Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study
{{output}}
Aims: Donanemab and Lecanemab are anti-amyloid monoclonal antibodies recently approved for the treatment of Alzheimer's disease. Although their efficacy and safety have been investigated in randomized trials, real-world epidemio... ...
